Over the past decade, immune checkpoint blockade (ICB) therapy has revolutionized the
outlook for oncology with significant and sustained improvement in the overall patient …

In a large number of cancer types, treatment selection depends on the presence of specific
tumor biomarkers. Due to the dynamic nature of cancer, very often these predictive …

Immune checkpoint blocking antibodies are a cornerstone in cancer treatment; however,
they benefit only a subset of patients and biomarkers to guide immune checkpoint blockade …

CD56+ T cells are generally recognized as a distinct population of T cells and are
categorized as NKT-like cells. Although our understanding of NKT-like cells is far from …

Background The predictive power of novel biological markers for treatment response to
immune checkpoint inhibitors (ICI) is still not satisfactory for the majority of patients with …

Currently, checkpoint inhibitor‐based immunotherapy has emerged as prevailing treatment
modality for diverse cancers. However, immunotherapy as a first‐line therapy has not …

Background A growing body of evidence suggests that T-cell responses against
neoantigens are critical regulators of response to immune checkpoint blockade. We …

Simple Summary Immunotherapy has revolutionized the therapeutic landscape of
melanoma. However, the absence of clinically validated predictive biomarkers is one of the …

Simple Summary Immune checkpoint inhibitors (ICIs) have revolutionized treatment of
advanced melanoma and survival of melanoma patients has radically improved since …

Anti-PD-(L) 1 therapy has shown great efficacy in some patients with cancer. However, a
significant proportion of patients with cancer do not respond to it. Another unmet clinical …